Time New York: Mon 23 Apr 05:32 am  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Landstar System (LSTR): Strong Industry, Solid Earnings Estimate Revisions

Zacks

One stock that might be an intriguing choice for investors right now is Landstar System, Inc. LSTR. This is because this security in the Transportation – Truck space is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Transportation – Truck space as it currently has a Zacks Industry Rank of 32 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Landstar System is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Landstar System, Inc. Price and Consensus

Landstar System, Inc. Price and Consensus | Landstar System, Inc. Quote


In fact, over the past month, current quarter estimates have risen from $1.23 per share to $1.32 per share, while current year estimates have risen from $5.15 per share to $5.47 per share. This has helped LSTR to earn a Zacks Rank #1 (Strong Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 Rank stocks here.

So, if you are looking for a decent pick in a strong industry, consider Landstar System. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.